Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia

Éva Matucz, Krisztina Móricz, Gábor Gigler, Annamária Simó, József Barkóczy, György Lévay, L. Hársing, G. Szénási

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Antagonists of 2-amino-3(3-hydroxy-5-methyl-4-isoxazolyl) propionic acid (AMPA) receptors can considerably reduce brain damage after cerebral ischemia, but effectiveness of selective AMPA antagonists has been questioned recently. Therefore, we evaluated the antiischemic efficacy of [±]-7-acetyl-5-[4- aminophenyl]-7,8-dihydro-8-cyano-8-methyl-9H-1,3-dioxolo-[4,5-h]-2, 3-benzodiazepine (EGIS-8332) and GYKI 53405, two selective, non-competitive AMPA antagonists in two rat models of focal cerebral ischemia. Permanent focal ischemia was produced by electrocoagulation of the middle cerebral artery (MCA). EGIS-8332 and GYKI 53405 were administered 30 min after MCA occlusion at doses of 1, 3 or 10 mg/kg i.p. In transient focal ischemia, MCA was occluded for 1 h and reperfused for 24 h using the intraluminal filament technique and the compounds were given at 3×10 mg/kg i.p. 60, 120 and 180 min following occlusion. In permanent focal ischemia, EGIS-8332 decreased the volume of cerebral infarction both at 10 mg/kg i.p. (36.4%, p

Original languageEnglish
Pages (from-to)210-216
Number of pages7
JournalBrain Research
Volume1019
Issue number1-2
DOIs
Publication statusPublished - Sep 3 2004

Fingerprint

GYKI 53405
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Ischemia
Middle Cerebral Artery
Brain Ischemia
Electrocoagulation
AMPA Receptors
Middle Cerebral Artery Infarction
Cerebral Infarction
Benzodiazepines
Brain
EGIS-8332

Keywords

  • Cerebral ischemia
  • Homophthalazine
  • Ischemia
  • J: Disorders of the nervous system
  • Middle cerebral artery occlusion
  • Neuroprotection

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia. / Matucz, Éva; Móricz, Krisztina; Gigler, Gábor; Simó, Annamária; Barkóczy, József; Lévay, György; Hársing, L.; Szénási, G.

In: Brain Research, Vol. 1019, No. 1-2, 03.09.2004, p. 210-216.

Research output: Contribution to journalArticle

Matucz, Éva ; Móricz, Krisztina ; Gigler, Gábor ; Simó, Annamária ; Barkóczy, József ; Lévay, György ; Hársing, L. ; Szénási, G. / Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia. In: Brain Research. 2004 ; Vol. 1019, No. 1-2. pp. 210-216.
@article{3d186e23c9234d9ea29c0093b145b9d2,
title = "Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia",
abstract = "Antagonists of 2-amino-3(3-hydroxy-5-methyl-4-isoxazolyl) propionic acid (AMPA) receptors can considerably reduce brain damage after cerebral ischemia, but effectiveness of selective AMPA antagonists has been questioned recently. Therefore, we evaluated the antiischemic efficacy of [±]-7-acetyl-5-[4- aminophenyl]-7,8-dihydro-8-cyano-8-methyl-9H-1,3-dioxolo-[4,5-h]-2, 3-benzodiazepine (EGIS-8332) and GYKI 53405, two selective, non-competitive AMPA antagonists in two rat models of focal cerebral ischemia. Permanent focal ischemia was produced by electrocoagulation of the middle cerebral artery (MCA). EGIS-8332 and GYKI 53405 were administered 30 min after MCA occlusion at doses of 1, 3 or 10 mg/kg i.p. In transient focal ischemia, MCA was occluded for 1 h and reperfused for 24 h using the intraluminal filament technique and the compounds were given at 3×10 mg/kg i.p. 60, 120 and 180 min following occlusion. In permanent focal ischemia, EGIS-8332 decreased the volume of cerebral infarction both at 10 mg/kg i.p. (36.4{\%}, p",
keywords = "Cerebral ischemia, Homophthalazine, Ischemia, J: Disorders of the nervous system, Middle cerebral artery occlusion, Neuroprotection",
author = "{\'E}va Matucz and Krisztina M{\'o}ricz and G{\'a}bor Gigler and Annam{\'a}ria Sim{\'o} and J{\'o}zsef Bark{\'o}czy and Gy{\"o}rgy L{\'e}vay and L. H{\'a}rsing and G. Sz{\'e}n{\'a}si",
year = "2004",
month = "9",
day = "3",
doi = "10.1016/j.brainres.2004.05.098",
language = "English",
volume = "1019",
pages = "210--216",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia

AU - Matucz, Éva

AU - Móricz, Krisztina

AU - Gigler, Gábor

AU - Simó, Annamária

AU - Barkóczy, József

AU - Lévay, György

AU - Hársing, L.

AU - Szénási, G.

PY - 2004/9/3

Y1 - 2004/9/3

N2 - Antagonists of 2-amino-3(3-hydroxy-5-methyl-4-isoxazolyl) propionic acid (AMPA) receptors can considerably reduce brain damage after cerebral ischemia, but effectiveness of selective AMPA antagonists has been questioned recently. Therefore, we evaluated the antiischemic efficacy of [±]-7-acetyl-5-[4- aminophenyl]-7,8-dihydro-8-cyano-8-methyl-9H-1,3-dioxolo-[4,5-h]-2, 3-benzodiazepine (EGIS-8332) and GYKI 53405, two selective, non-competitive AMPA antagonists in two rat models of focal cerebral ischemia. Permanent focal ischemia was produced by electrocoagulation of the middle cerebral artery (MCA). EGIS-8332 and GYKI 53405 were administered 30 min after MCA occlusion at doses of 1, 3 or 10 mg/kg i.p. In transient focal ischemia, MCA was occluded for 1 h and reperfused for 24 h using the intraluminal filament technique and the compounds were given at 3×10 mg/kg i.p. 60, 120 and 180 min following occlusion. In permanent focal ischemia, EGIS-8332 decreased the volume of cerebral infarction both at 10 mg/kg i.p. (36.4%, p

AB - Antagonists of 2-amino-3(3-hydroxy-5-methyl-4-isoxazolyl) propionic acid (AMPA) receptors can considerably reduce brain damage after cerebral ischemia, but effectiveness of selective AMPA antagonists has been questioned recently. Therefore, we evaluated the antiischemic efficacy of [±]-7-acetyl-5-[4- aminophenyl]-7,8-dihydro-8-cyano-8-methyl-9H-1,3-dioxolo-[4,5-h]-2, 3-benzodiazepine (EGIS-8332) and GYKI 53405, two selective, non-competitive AMPA antagonists in two rat models of focal cerebral ischemia. Permanent focal ischemia was produced by electrocoagulation of the middle cerebral artery (MCA). EGIS-8332 and GYKI 53405 were administered 30 min after MCA occlusion at doses of 1, 3 or 10 mg/kg i.p. In transient focal ischemia, MCA was occluded for 1 h and reperfused for 24 h using the intraluminal filament technique and the compounds were given at 3×10 mg/kg i.p. 60, 120 and 180 min following occlusion. In permanent focal ischemia, EGIS-8332 decreased the volume of cerebral infarction both at 10 mg/kg i.p. (36.4%, p

KW - Cerebral ischemia

KW - Homophthalazine

KW - Ischemia

KW - J: Disorders of the nervous system

KW - Middle cerebral artery occlusion

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=4043102491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4043102491&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2004.05.098

DO - 10.1016/j.brainres.2004.05.098

M3 - Article

C2 - 15306255

AN - SCOPUS:4043102491

VL - 1019

SP - 210

EP - 216

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -